45-P

Abstract

Aim The Contribution of MICA antibodies to AMR and poor transplant outcomes have been described by multiple reports. In order to evaluate the prevalence of these antibodies in allosensitized kidney transplant candidates on our deceased donor waiting list, we tested patients that were positive for the presence of HLA Class I and/or Class II for the presence of MICA antibodies. Methods A total of 200 patients were tested for the presence of Class I and Class II HLA antibodies using Screen De Luxe Life Codes. The patients that tested positive for HLA antibodies Class I and/or Class II were tested for the presence of MICA antibodies using LifeCodes LSA-MIC. Results Of the 200 patients on the waiting list for deceased kidney donors, 55 (28%) were positive for anti HLA Class I and /or Class II antibodies, 25 (45%) were positive for HLA Class I and II antibodies; 21 (38%) patients were positive for HLA Class I antibodies only; 9 (16%) patients were positive for Class II antibodies only. We tested the presence of MICA antibodies in the 55 sera positive for HLA antibodies, of these 11 (20%) were positive for MICA antibodies. 7/55 (13%) patients were positive for MICA and HLA Class I and Class II antibodies. The most frequency MICA antibodies is MICA∗041 (5/11= 45%). Conclusions Our results indicate that MICA antibodies are present in a significant proportion of HLA allosensitized patients. These findings are clinically relevant to both donor selection and post-transplant monitoring strategies and warrants further investigation.